{"schema_version":"secwatch.filing_event.v1","accession":"0000832101-22-000054","form_type":"8-K","ticker":"IEX","cik":"0000832101","company_name":"IDEX CORP /DE/","filed_at":"2022-10-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.685216+00:00","generated_at":"2026-06-23T01:03:03.233505+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"IDEX Q3 record EPS $2.36 (adjusted $2.14), sales $824M +16%, raises FY guidance","bullets":["Record Q3 sales $824M (+16% overall, +15% organic YoY); operating margin 24.5% (adj. 24.9%).","Record EPS $2.36 (adj. $2.14), up 56%/20% YoY; cash from ops $198M, free cash flow $182M.","FY2022 guidance raised: GAAP EPS $7.75–$7.80, adj. EPS $8.04–$8.09; organic sales growth ~12%.","Acquired Muon Group for €700M (closing expected Q4 2022); completed sale of Knight for $49.4M.","Exited COVID-19 testing application: $16.8M impairment, $17.9M deferred revenue acceleration (net $1.1M)."],"urls":{"canonical":"https://secwatch.observer/filing/0000832101-22-000054","json":"https://secwatch.observer/filing/0000832101-22-000054.json","markdown":"https://secwatch.observer/filing/0000832101-22-000054.md","text":"https://secwatch.observer/filing/0000832101-22-000054.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/832101/000083210122000054/0000832101-22-000054-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/832101/000083210122000054/iex-20221025.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T01:03:03.233505+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}